Market capitalization | $81.18m |
Enterprise Value | $56.10m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.63 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-39.37m |
Free Cash Flow (TTM) Free Cash Flow | $-35.28m |
Cash position | $49.75m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
6 Analysts have issued a PDS Biotechnology Corp. forecast:
6 Analysts have issued a PDS Biotechnology Corp. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.06 -0.06 |
67%
67%
|
|
EBITDA | -39 -39 |
23%
23%
|
EBIT (Operating Income) EBIT | -39 -39 |
23%
23%
|
Net Profit | -41 -41 |
21%
21%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.
Head office | United States |
CEO | Frank Bedu-Addo |
Employees | 25 |
Founded | 2005 |
Website | www.pdsbiotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.